The Rationale for Exploring Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma

Combination therapy with nanatinostat and valganciclovir led to promising response rates among patients with Epstein-Barr Virus-positive peripheral T-cell lymphoma.

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

Aaron Lisberg, MD, discussed the phase 3 TROPION-Lung01 study which evaluated datopotamab deruxtecan for patients with advanced or metastatic non-small cell lung cancer.

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

Jeff Yorio, MD, discussed the unmet needs among patients with melanoma and plans for a phase 3 study assessing an mRNA vaccine.

In an interview with Targeted Oncology, Sara Kerr, MD discussed the evolution of genomic testing for patients with cancer and highlighted the program used at Allina Health.